| Bivariate small‐area estimation for binary and gaussian variables based on a conditionally specified model H Sun, E Berg, Z Zhu Biometrics, 2021 | 10 | 2021 |
| Multivariate Small-area Estimation for Mixed-type Response Variables With Item Nonresponse H Sun, E Berg, Z Zhu Journal of Survey Statistics and Methodology, 2023 | 2 | 2023 |
| PKBOIN‐12: A Bayesian Optimal Interval Phase I/II Design Incorporating Pharmacokinetics Outcomes to Find the Optimal Biological Dose H Sun, J Tu Pharmaceutical Statistics, 2023 | 2 | 2023 |
| Phase 1b OMNIVERSE trial: Safety and tolerability of oral azacitidine (Oral-AZA) in combination with venetoclax (VEN) for treatment of acute myeloid leukemia. S Fleming, GJ Roboz, AT Fathi, TY Zhang, A Wei, HE Carraway, L Holes, ... Journal of Clinical Oncology 41 (16_suppl), e19011-e19011, 2023 | 1 | 2023 |
| A Comparative Evaluation of Bayesian Model-Assisted Two-Stage Designs for Phase I/II Clinical Trials H Sun, J Li arXiv preprint arXiv:2501.08410, 2025 | | 2025 |
| Statistical operating characteristics of current early phase dose finding designs with toxicity and efficacy in oncology H Sun, HY Lin, J Tu, R Ananthakrishnan, E Kim Journal of Biopharmaceutical Statistics, 1-21, 2024 | | 2024 |
| Phase IB OMNIVERSE Trial: Safety and Tolerability of Oral Azacitidine (Oral-AZA) in Combination With Venetoclax (VEN) for Treatment of Acute Myeloid Leukemia (AML) S Fleming, GJ Roboz, AT Fathi, TY Zhang, A Wei, HE Carraway, L Holes, ... CLINICAL LYMPHOMA MYELOMA & LEUKEMIA 23, S293-S293, 2023 | | 2023 |
| POSTER: AML-370 Phase IB OMNIVERSE Trial: Safety and Tolerability of Oral Azacitidine (Oral-AZA) in Combination With Venetoclax (VEN) for Treatment of Acute Myeloid Leukemia (AML) S Fleming, GJ Roboz, AT Fathi, TY Zhang, A Wei, HE Carraway, L Holes, ... Clinical Lymphoma Myeloma and Leukemia 23, S168, 2023 | | 2023 |
| AML-370 Phase IB OMNIVERSE Trial: Safety and Tolerability of Oral Azacitidine (Oral-AZA) in Combination With Venetoclax (VEN) for Treatment of Acute Myeloid Leukemia (AML) S Fleming, GJ Roboz, AT Fathi, TY Zhang, A Wei, HE Carraway, L Holes, ... Clinical Lymphoma Myeloma and Leukemia 23, S293, 2023 | | 2023 |
| P567: PHASE 1B OMNIVERSE TRIAL: SAFETY AND TOLERABILITY OF ORAL AZACITIDINE IN COMBINATION WITH VENETOCLAX FOR TREATMENT OF ACUTE MYELOID LEUKEMIA S Fleming, G Roboz, AT Fathi, TY Zhang, A Wei, H Carraway, L Holes, ... HemaSphere 7 (S3), e27202d1, 2023 | | 2023 |
| PHASE 1B OMNIVERSE TRIAL: SAFETY AND TOLERABILITY OF ORAL AZACITIDINE IN COMBINATION WITH VENETOCLAX FOR TREATMENT OF ACUTE MYELOID LEUKEMIA S Fleming, G Roboz, AT Fathi, TY Zhang, A Wei, H Carraway, L Holes, ... European Hematology Association 386396, P567, 2023 | | 2023 |
| Do Messages Matter in Conservation Practice Adoptions? Evidence from a Farmer Information Treatment X Wan, H Sun, J Comito, W Zhang | | 2023 |
| Small area estimation and graphical model for complex surveys H Sun | | 2022 |
| A PENALIZED H-LIKELIHOOD METHOD FOR GAUSSIAN SPATIAL ADDITIVE MODEL ON REGULAR LATTICE H Sun | | 2019 |
Zhengyuan ZhuProfessor of Statistics, Iowa State Universityبريد إلكتروني تم التحقق منه على iastate.edu
